ArticleChinese journal of cancer research = Chung-kuo yen cheng yen chiu2026
Spatial transcriptome revealed associated biomarkers for endocrine therapy response in HR-positive/HER2-negative early breast cancer.
Article in Chinese journal of cancer research = Chung-kuo yen cheng yen chiu, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Endocrine resistance occurs in nearly all patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer (EBC), which can develop local and distant recurrence. The situation highlights the need to explore biomarkers for the efficacy of endocrine therapy (ET). Methods: We performed digital spatial profiling on postoperative tumor samples from 20 HR+/HER2- EBC patients receiving adjuvant tamoxifen therapy, based on a designated panel comprising 235 ET-related genes. Paired patients were stratified into resistant and sensitive groups based on ET response. A total of 111 regions in three tissue compartments defined by morphology markers [tumor (PANCK+), leucocytes (CD45+), and nonimmune stroma (CD45-/PANCK-)] were investigated for immune and transcriptomic biomarkers. Results: A total of 27, 13, and 5 differentially expressed genes (DEGs) were identified in PANCK+, CD45+, and CD45-/PANCK- regions. In the PANCK+ regions, mRNA expression of fourteen DEGs was significantly associated with disease-free survival (DFS), among which seven DEGs were further selected to construct a model for DFS. In the model, patients with low-risk scores had a median DFS of 55.77 months, significantly longer than 21.67 months among those with high-risk scores [P=2.1e-4, hazard ratio (HR)=6.73, 95% confidence interval (95% CI) =2.20-20.60)]. The area under curve for 1-year, 3-year, and 5-year DFS was 0.98, 0.95, and 0.91, indicating its superior efficacy. ET-sensitive patients had significantly higher non-classical monocyte infiltration in the CD45+ regions (P=0.03), whereas ET-resistant patients had significantly higher plasma cell infiltration in the CD45-/PANCK- regions (P=0.01). Conclusions: Our study has first demonstrated the spatial transcriptomic landscapes of patients with different responses to ET, which may help stratify patients who are responsive to ET and motivate the exploration of the molecular mechanisms of endocrine resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.